All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Alexey Danilov, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What is the most promising new targetable pathway in chronic lymphocytic leukemia?
What is the most promising new targetable pathway in CLL?
Danilov begins by highlighting that preclinical studies are currently focusing on several targets, such as B-cell receptor pathways and Bruton's tyrosine kinase inhibitors, which are close to entering everyday clinical practice. Cell apoptosis also remains a promising target with multiple novel agents being investigated further, such as those targeting Bcl-X. Finally he discusses the promise of immunotherapy such as CAR T-cell therapy and bispecific antibodies.
ASH 2019 | Practice-changing abstracts in lymphoma and CLL
The Lymphoma Hub has developed a downloadable resource, which provides an update on the practice-changing abstracts in lymphoma and CLL from ASH 2019 in preparation for ASH 2020.
Educational theme: Advances in T-cell lymphomas
Throughout May, the Lymphoma Hub will be focusing on a new educational theme of “Advances in T-cell lymphomas”. This article introduces the topic of T-cell lymphomas and summarizes some of the latest...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox